No Data
Express News | National Medical Products Administration: Deploys pilot work on segmented production reform of biological products.
Who's buying? The A-share market is closed, but the Hong Kong stock market is still going strong! There's a big shift in foreign capital underway.
According to the latest report published by Goldman Sachs, after the People's Bank of China announced easing measures and the September Political Bureau meeting, mainland consumer stocks rebounded strongly by an average of about 32% in the past week.
Express News | Hong Kong stock CRO concept stocks soared at the close, what happened?
AUSTAR: 2024 Interim Report
The interim net profit of austar (06118.HK) is 5.88 million RMB, turning from loss to profit.
Austar Life Sciences and Technology (06118.HK) announced its interim performance for the six months ending in June, with revenue of 701 million RMB (same below), a year-on-year decrease of 23.8%. It recorded a net profit of 5.88 million yuan, compared to a loss of 39.94 million yuan in the same period last year, turning losses into profits; earnings per share were 1 cent. No interim dividend is declared.
Austar Life Sciences (06118.HK): Achieved revenue of 0.701 billion yuan in the first half.
Austar Life Technology (06118.HK) announced on August 27th that for the six months ended June 30, 2024, the Group recorded revenue of approximately RMB 0.701 billion, a decrease of RMB 0.219 billion compared to the first half of 2023, mainly due to a 32.7% decrease in the Group's order volume for the entire year of 2023, resulting in a reduction in unfinished contracts at the beginning of the period. However, compared to the loss recorded in the first half of 2023, the net income after tax for the first half of 2024 has turned from a loss to a profit, and the order intake for the first half of 2024 has increased by 25% compared to the same period in 2023.
No Data
No Data